[Directly observed therapy (DOT): from tuberculosis to HIV].
BACKGROUND
Combination antiretroviral therapy, which is the standard of care since 1996, has been demonstrated to be very effective in suppressing plasma viral load in patients infected with HIV. Optimal benefit from antiretroviral drugs, however, is obtained when the patient adheres strictly to the rigorous treatment regimen. For some patients it is difficult to obtain good adherence to antiretroviral regimens. In response to these concerns, different strategies, such as directly observed therapy, have been proposed to attempt to improve adherence to antiretroviral treatment. Directly observed therapy is a strategy that has its roots in the treatment of tuberculosis and it consists essentially of taking the medication in the presence of a health care provider or another designated person. This strategy has been recently tried in the treatment of HIV but its efficacy remains unknown.


METHODS
A Medline and Medscape search was performed to review all pertinent publications on the use of directly observed therapy in HIV infection.


RESULTS
Twenty-five papers published between 1996 and 2004 were selected. Almost all the studies were performed in industrialized countries in North America and Europe. The majority of the studies are retrospective, six of them comparing at least two strategies (directly observed therapy vs standard of care). Only one randomized trial has been found. The patients involved in the studies are intravenous drug users or particularly non-adherent patients. Almost all studies show a better rate of adherence or a better control of the viremia in patients on directly observed therapy.


CONCLUSIONS
The directly observed therapy seems to be a valuable and feasible way to raise the adherence rate in HIV patients with a problem of non-adherence to antiretroviral treatments. Clinical trials are needed to evaluate the efficacy of this strategy to raise the adherence rate among patients who need additional support to take their antiretrovirals.
Machouf
N
N
Centre Hospitalier Universitaire McGill, Université McGill, Montréal, Québec, Canada. mmachouf@lactuel.ca
Lalonde
R-G
RG
D023241:Antiretroviral Therapy, Highly Active; D023801:Directly Observed Therapy; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance